PL4092020T3 - Stałe postacie inhibitora kapsydu hiv - Google Patents

Stałe postacie inhibitora kapsydu hiv

Info

Publication number
PL4092020T3
PL4092020T3 PL22165005.4T PL22165005T PL4092020T3 PL 4092020 T3 PL4092020 T3 PL 4092020T3 PL 22165005 T PL22165005 T PL 22165005T PL 4092020 T3 PL4092020 T3 PL 4092020T3
Authority
PL
Poland
Prior art keywords
solid forms
hiv capsid
capsid inhibitor
inhibitor
hiv
Prior art date
Application number
PL22165005.4T
Other languages
English (en)
Inventor
Bing Shi
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL4092020T3 publication Critical patent/PL4092020T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL22165005.4T 2017-08-17 2018-08-16 Stałe postacie inhibitora kapsydu hiv PL4092020T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762546968P 2017-08-17 2017-08-17

Publications (1)

Publication Number Publication Date
PL4092020T3 true PL4092020T3 (pl) 2024-11-04

Family

ID=63528873

Family Applications (2)

Application Number Title Priority Date Filing Date
PL22165005.4T PL4092020T3 (pl) 2017-08-17 2018-08-16 Stałe postacie inhibitora kapsydu hiv
PL18766406.5T PL3668859T3 (pl) 2017-08-17 2018-08-16 Stałe postacie inhibitora kapsydu HIV

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18766406.5T PL3668859T3 (pl) 2017-08-17 2018-08-16 Stałe postacie inhibitora kapsydu HIV

Country Status (14)

Country Link
US (3) US11267799B2 (pl)
EP (3) EP4458415A3 (pl)
JP (2) JP7136886B2 (pl)
KR (2) KR102399483B1 (pl)
CN (2) CN111051296A (pl)
AR (1) AR112413A1 (pl)
AU (4) AU2018317833C1 (pl)
CA (2) CA3070141C (pl)
ES (2) ES2916426T3 (pl)
PL (2) PL4092020T3 (pl)
PT (1) PT3668859T (pl)
SI (1) SI3668859T1 (pl)
TW (2) TWI687415B (pl)
WO (1) WO2019035904A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
BR112018071678B1 (pt) 2016-08-19 2021-01-26 Gilead Sciences, Inc. compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
TWI823164B (zh) * 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
CA3216031A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
EP3914604A4 (en) 2019-01-25 2022-10-19 Brown University COMPOSITIONS AND METHODS FOR TREATMENT, PREVENTION OR REVERSE OF AGE-RELATED INFLAMMATION AND DISEASE
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
TWI854067B (zh) 2019-11-26 2024-09-01 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
TW202128660A (zh) 2019-11-29 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合吡啶環衍生物、其製備方法及其在醫藥上的應用
WO2021176366A1 (en) 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP2023517312A (ja) 2020-03-06 2023-04-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
TW202502766A (zh) * 2020-06-25 2025-01-16 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
WO2022159877A1 (en) 2021-01-25 2022-07-28 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
EP4361140A4 (en) * 2021-05-28 2025-09-03 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF FUSED CYCLIC PYRIDINE DERIVATIVE AND PROCESS FOR PREPARATION THEREOF
MX2024004551A (es) * 2021-10-13 2024-06-26 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.
TW202342448A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
EP4440701A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
EP4440702B1 (en) 2021-12-03 2025-05-21 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
CN121219281A (zh) 2023-05-31 2025-12-26 吉利德科学公司 用于治疗hiv的化合物的固体形式
US20250011353A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Process of preparing hiv capsid inhibitor
CN116675675A (zh) * 2023-06-05 2023-09-01 北京康立生医药技术开发有限公司 一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法
WO2024257009A1 (en) 2023-06-15 2024-12-19 VIIV Healthcare UK (No.5) Limited Methods and intermediates for preparing compounds
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025083656A1 (en) * 2023-10-20 2025-04-24 Apitoria Pharma Private Limited Novel crystalline form of lenacapavir sodium and processes for its preparation
US20250367386A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367382A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367381A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240387A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367385A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1007198A (en) 1911-05-24 1911-10-31 Richard D Hayward Egg-candler.
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
WO1991019721A1 (en) 1990-06-13 1991-12-26 Arnold Glazier Phosphorous produgs
ES2118069T3 (es) 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
WO2003002553A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
ATE380175T1 (de) 2001-06-27 2007-12-15 Smithkline Beecham Corp Pyrrolidine als dipeptidyl peptidase inhibitoren
AU2002334205B2 (en) 2001-10-26 2007-07-05 Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
ATE434621T1 (de) 2004-02-27 2009-07-15 Schering Corp Neue verbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
WO2006083687A1 (en) 2005-01-28 2006-08-10 Cardiome Pharma Corp. Crystal salt of xanthine oxidase inhibitors
TW200726755A (en) 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
EA014245B1 (ru) 2005-12-14 2010-10-29 Бристол-Маерс Сквибб Компани Аналоги арилпропионамида, арилакриламида, арилпропинамида или арилметилмочевины в качестве ингибиторов фактора xia
PL2010493T3 (pl) 2006-04-12 2016-08-31 Merck Sharp & Dohme Pirydyloamidy jako antagoniści kanałów wapniowych typu t
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
CA2681718A1 (en) 2007-03-23 2008-10-02 University Of Massachusetts Hiv-1 protease inhibitors
MX2009013830A (es) 2007-06-29 2010-03-01 Gilead Sciences Inc Compuestos antivirales.
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
JP5524071B2 (ja) 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
AU2008317352A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
NZ585226A (en) 2007-11-16 2012-08-31 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
WO2009114677A1 (en) 2008-03-13 2009-09-17 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
ES2438496T3 (es) 2008-08-01 2014-01-17 Ventirx Pharmaceuticals, Inc. Formulaciones de agonistas de receptores de tipo toll y su uso
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
US20120045761A1 (en) 2009-02-25 2012-02-23 Bigtec Private Limited Probes and primers for detection of chikungunya
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
CN102753542B (zh) 2009-08-18 2016-01-20 文蒂雷克斯药品公司 作为t0ll样受体调节剂的取代的苯并氮杂*
RU2016108987A (ru) 2009-08-18 2018-11-26 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
PH12013500011A1 (en) 2010-07-02 2013-02-18 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat aids
NZ604716A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
NZ608673A (en) 2010-10-01 2015-04-24 Univ Pennsylvania Therapeutic use of a tlr agonist and combination therapy
JP6092107B2 (ja) 2010-10-01 2017-03-08 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アレルギー性疾患の治療方法
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
EP3207930A1 (en) 2011-01-12 2017-08-23 VentiRx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
HRP20170401T1 (hr) 2011-01-12 2017-05-19 Ventirx Pharmaceuticals, Inc. SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA
HUE054055T2 (hu) 2011-03-23 2021-08-30 Trevena Inc Opoid receptor ligandumok és eljárás azok alkalmazására és elõállítására
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
JP5918848B2 (ja) 2011-04-21 2016-05-18 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール化合物およびその薬学的使用
AU2012258220B2 (en) 2011-05-18 2017-01-19 Janssen Sciences Ireland Uc Quinazoline derivatives for the treatment of viral infections and further diseases
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
SG11201402660YA (en) 2011-12-21 2014-10-30 Novira Therapeutics Inc Hepatitis b antiviral agents
DK2812331T3 (en) 2012-02-08 2019-04-08 Janssen Sciences Ireland Unlimited Co PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
US20150104511A1 (en) 2012-03-05 2015-04-16 Cipla Limited Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
AU2013301450B2 (en) * 2012-08-10 2018-01-18 Janssen Sciences Ireland Uc Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
DK2906563T3 (en) * 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
NZ706226A (en) 2012-11-16 2019-09-27 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2940019B1 (en) 2012-12-27 2018-03-28 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
NZ631726A (en) 2013-01-09 2017-01-27 Gilead Sciences Inc Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
WO2014110323A1 (en) 2013-01-11 2014-07-17 Johnson Controls Technology Company Vehicle interior component having a wireless charging indicator
CN105189468B (zh) * 2013-02-21 2018-10-30 爱尔兰詹森科学公司 用于治疗病毒性感染的2-氨基嘧啶衍生物
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
TWI706945B (zh) * 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
KR20160078382A (ko) 2013-10-24 2016-07-04 브리스톨-마이어스 스큅 컴퍼니 인간 면역결핍 바이러스 복제의 억제제
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
BR112017013491A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de pirimidina fundida para o tratamento de hiv
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
PL3321265T3 (pl) 2015-03-04 2020-11-16 Gilead Sciences, Inc. Związki 4,6-diamino-pirydo[3,2-d]pirymidynowe i ich wykorzystanie jako modulatorów receptorów toll-podobnych
AR104389A1 (es) 2015-04-23 2017-07-19 Bristol Myers Squibb Co Inhibidores de la replicación del virus de inmunodeficiencia humana
UY36649A (es) 2015-04-23 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112017026406A2 (pt) 2015-06-12 2019-04-02 Adhaere Pharmaceuticals, Inc. formas sólidas de ácido (z)-4-(5-((3-benzil-4-oxo-2-tioxotiazolidin-5-ilideno)metil)furan-2-il)benzoico
IL293770B2 (en) 2015-07-06 2023-07-01 Gilead Sciences Inc Modulators of cot and methods of using them
AU2016383059B2 (en) 2015-12-28 2022-10-27 Monsanto Technology Llc Stable inoculant compositions and methods for producing same
BR112018071678B1 (pt) 2016-08-19 2021-01-26 Gilead Sciences, Inc. compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas
CA3035346A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
TWI687415B (zh) * 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI803530B (zh) 2017-10-27 2023-06-01 美商普雷辛肯公司 調節激酶之化合物之調配物
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
CA3216031A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
TWI854067B (zh) 2019-11-26 2024-09-01 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
TW202502766A (zh) 2020-06-25 2025-01-16 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
TW202342448A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
EP4440702B1 (en) 2021-12-03 2025-05-21 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
US20250057826A1 (en) 2023-07-28 2025-02-20 Gilead Sciences, Inc. Weekly regimen for hiv
US20250090513A1 (en) 2023-08-23 2025-03-20 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor

Also Published As

Publication number Publication date
US20220251069A1 (en) 2022-08-11
TW202024061A (zh) 2020-07-01
PL3668859T3 (pl) 2022-07-18
US11845739B2 (en) 2023-12-19
US20240254104A1 (en) 2024-08-01
EP3668859B1 (en) 2022-03-30
KR20200039761A (ko) 2020-04-16
US12492189B2 (en) 2025-12-09
EP3668859A1 (en) 2020-06-24
CA3070141C (en) 2023-03-07
EP4092020A1 (en) 2022-11-23
SI3668859T1 (sl) 2022-07-29
EP4092020B1 (en) 2024-07-10
CN111051296A (zh) 2020-04-21
KR102497602B1 (ko) 2023-02-08
EP4458415A2 (en) 2024-11-06
AU2021206907B2 (en) 2022-11-24
AU2021206907A1 (en) 2021-08-19
AU2018317833A1 (en) 2020-02-06
AU2018317833B2 (en) 2021-05-06
AU2021250894B2 (en) 2023-11-16
US20190084963A1 (en) 2019-03-21
AU2018317833C1 (en) 2021-10-28
US11267799B2 (en) 2022-03-08
AU2021250894A1 (en) 2021-11-25
PT3668859T (pt) 2022-07-08
TWI687415B (zh) 2020-03-11
KR20220070051A (ko) 2022-05-27
EP4458415A3 (en) 2025-01-15
EP4092020C0 (en) 2024-07-10
CA3070141A1 (en) 2019-02-21
JP2020531434A (ja) 2020-11-05
AU2021250891B2 (en) 2023-11-23
JP2021191798A (ja) 2021-12-16
JP7136886B2 (ja) 2022-09-13
AU2021250891A1 (en) 2021-12-02
ES2991698T3 (es) 2024-12-04
KR102399483B1 (ko) 2022-05-19
WO2019035904A1 (en) 2019-02-21
CA3176006A1 (en) 2019-02-21
CN117285514A (zh) 2023-12-26
AR112413A1 (es) 2019-10-23
TW201920140A (zh) 2019-06-01
ES2916426T3 (es) 2022-07-01

Similar Documents

Publication Publication Date Title
PL4092020T3 (pl) Stałe postacie inhibitora kapsydu hiv
PL3668860T3 (pl) Formy soli cholinowej inhibitora kapsydu wirusa hiv
IL268282B (en) hiv inhibitory compounds
IL273842A (en) 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as HIV protease inhibitors
ZA201807865B (en) Formulations of an lsd1 inhibitor
IL252756A0 (en) solid forms of ask1 inhibitor
IL257026A (en) Solid state forms of eluxadoline
IL257061A (en) Inhibitors of ezh2
IL274627A (en) Solid forms of valbenazine
IL265628A (en) Solid state forms of valbenazine
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
EP3193939A4 (en) Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
ZA201706282B (en) Solid forms of menaquinols
IL276107A (en) Crystalline forms of psoorstam
SG10202103332UA (en) Solid forms of ttk inhibitor
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
HK40100506A (zh) Hiv衣壳抑制剂的固体形式
ZA201808437B (en) Determination of feedback timing
IL254666A0 (en) Crystalline forms of Aldecalcitol
HK40099486A (zh) Hiv衣壳抑制剂的胆碱盐形式
IL283421A (en) Crystalline forms of Refroxlap
GB201721386D0 (en) Chrondogy of time-wave
GB201706876D0 (en) Detection of HIV enzymes
PH32015000758S1 (en) Set of earbuds